Clevidipine: A short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension

Pharmacotherapy

Volumn 30, Issue 5, 2010, Pages 515-528

  Erickson, Abbie L ^a   DeGrado, Jeremy R ^a   Fanikos, John R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute postoperative hypertension; Antihypertensive; Blood pressure; Clevidipine; Dihydropyridine calcium channel blocker; Hypertensive emergency; Hypertensive urgency; Perioperative hypertension

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLEVIDIPINE; CLONIDINE; DIHYDROPYRIDINE; DILTIAZEM; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; LOOP DIURETIC AGENT; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PROPOFOL; VERAPAMIL;

ACUTE KIDNEY FAILURE; AORTA DISSECTION; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST OF ILLNESS; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECLAMPSIA; FLUSHING; HEART ATRIUM FIBRILLATION; HEART INDEX; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART SURGERY; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; KIDNEY ISCHEMIA; LUNG EDEMA; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PATIENT MONITORING; PERIOPERATIVE COMPLICATION; PERIOPERATIVE HYPERTENSION; POLYURIA; PREECLAMPSIA; RENAL PROTECTION; REVIEW; SIDE EFFECT; SYNCOPE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC DYSFUNCTION; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIAC SURGICAL PROCEDURES; EMERGENCY TREATMENT; HUMANS; HYPERTENSION; PYRIDINES; VASODILATOR AGENTS;

EID: 77951754712     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.5.515     Document Type: Review

References (42)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572
2. Kaplan NM. Clinical hypertension, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:4.
3. Marik P, Varon J. Hypertensive crises: challenges and management. Chest 2007;131:1949-1962
4. Slama M, Modeliar S. Hypertension in the intensive care unit. Curr Opin Cardiol 2006;21:279-287
5. National Center for Health Statistics. Vital and health statistics: detailed diagnoses and procedures for patients discharged from short-stay hospitals: United States, 1983-1990. Hyattsville, MD: National Center for Health Statistics, 1997.
6. Gal TJ, Cooperman LH. Hypertension in the immediate postoperative period. Br J Anaesth 1975;47:70-74
7. Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery. Br J Anaesth 2001;86:798-803
8. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996;276:1328-1331
9. Lund-Johansen P. Pharmacology of combined alpha-beta blockade. II. Haemodynamic effects of labetalol. Drugs 1984;28(suppl 2):35-50.
10. Kanot J, Allonen H, Kleimola T, Mantyla R. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1981;19:41-44
11. Marty J, Kirsteter P, Cantineau JP, et al. Esmolol attenuation of hemodynamic changes in resuscitation of hypertensive and coronary patients [letter, in French]. Ann Fr Anesth Reanim 1989;8(suppl):R95.
12. Wiest DB, Garner SS, Uber WE, Sade RM. Esmolol for the management of pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg 1998;115:890-897
13. The Medicines Company. Cleviprex (clevidipine butyrate) package insert. Parsippany, NJ; 2008.
14. Poelaert J, Roosens C. Perioperative use of dihydropyridine calcium channel blockers. Acta Anesthesiol Scand 2000;44:528-535
15. 2+ currents: steady-state and kinetic electrophysiological studies in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2000;36:592-600.
16. Lammerhofer M, Gyllenhaal O, Lindner W. HPLC enantiomer separation of a chiral 1,4-dihydropyridine monocarboxylic acid. J Pharm Biomed Anal 2004;35:259-266
17. Schwieler JH, Ericsson H, Loefdahl P, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra-short-acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol 1999;34:268-274
18. Ericsson H, Fakt C, Hoglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol 1999;55:61-67
19. Ericsson H, Schwieler J, Lindmark BO, et al. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality 2001;13:130-134
20. Ericsson H, Fakt C, Jolin-Mellgard A, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 1999;47:531-538
21. Vuylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth 2000;85:683-689
22. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1 (ESCAPE-1). Anesth Analg 2007;105:918-925
23. Kieler-Jensen N, Jolin-Mellgard A, Nordlander M, et al. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 2000;44:186-193
24. Segawa D, Sjoequist PO, Nordlander M, et al. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur J Pharmacol 1999;380:123-128
25. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens 2002;24:301-313
26. Segawa D, Sjoequist PO, Wang QD, et al. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine. J Cardiovasc Pharmacol 2000;36:338-343
27. Odenstedt J, Mansson C, Grip L. Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J Cardiovasc Pharmacol 2004;44:407-415
28. Gourine A, Gonon A, Sjoequist PO, et al. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium. Cardiovasc Res 2001;51:100-107
29. Ericsson H, Bredburg U, Eriksson U, et al. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology 2000;92:993-1001.
30. Ericsson H, Tholander B, Regardh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci 1999;8:29-37.
31. Ericsson H, Tholander B, Bjorkman JA, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos 1999;27: 558-564
32. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients, a dose-finding study. Anesthesiology 2002;96:1086-1094
33. Zhang JG, Dehal SS, Ho T, et al. Human cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab Disp 2006;34:34:734-737
34. Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg 2008;107:59-67.
35. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008;107:1110-1121
36. Pollack C, Varon J, Garrison N, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 2009;53:329-338
37. Powroznyk AV, Vuylsteke A, Naughton C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003;20:697-703.
38. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Application number NDA 022156. Summary review and medical review. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist. Accessed September 24, 2008.
39. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005;103:860-876
40. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-154
41. U.S. National Institutes of Health. ClinicalTrials.gov. Clevidipine. Available from www.clinicaltrials.gov. Accessed May 11, 2009.
42. PDR Staff, eds. Red book: pharmacy's fundamental reference, 2008. Montvale, NJ: Thomson Healthcare, 2008.